Why Is INTEGRA LIFESCIENCES (IART) Stock Down Today?

Integra LifeSciences (IART) fell 20.73% to $12.76 in a sharply declining session driven by the company’s announcement of a cut to its 2026 financial guidance. The move followed a severe flooding event at its Cincinnati facility, which disrupted supply chains and led to estimated revenue reductions of $7 million in Q3 and $15 million to $20 million in Q4. The company revised its full-year 2026 adjusted EPS outlook to a range of $2.30, $2.40 from $2.40, $2.50 and lowered revenue guidance to $1.634 billion, $1.654 billion from $1.654 billion, $1.695 billion.

What Happened The stock opened at $16.13 but quickly fell throughout the session, reaching a low of $12.72 before closing near that level. The company disclosed preliminary Q3 2026 results and outlined the operational and financial impact of the flood, which caused supply disruptions and delayed product availability. The revised guidance reflects the company’s expectation of reduced cash flow and earnings for the remainder of the year. The Fly reported that Integra LifeSciences cut its FY26 adjusted EPS view to $2.30, $2.40 from $2.40, $2.50. The flood-related headwinds were described as a key factor in the decision.

What The Data Shows The stock has declined 13.0% over the past eight sessions, from $15.53 to $13.50. On October 2, the stock printed 10 fresh 52-week lows, while also hitting three 52-week highs. The session volume of 0.8 million shares was 0.9 times the 3-month average. The stock opened at a 52-week high but fell sharply, closing near its session low. The company’s fundamentals remain unprofitable, with a trailing 12-month net margin of -0.4% and a market cap of $1.3 billion.

What To Watch The company’s full-year 2026 earnings report will be a key event to monitor, as will any updates on the recovery of the Cincinnati facility and the impact on future cash flow projections.